ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
0,00%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,965
-0,05%
Bitcoin
64 611,98
-0,32%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Oramed Pharmaceuticals Inc (ORMP)

  7. Oramed Pharmaceuticals Inc (ORMP) Actualités

ORMP

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ORMP
DateHeureSourceTitreSymboleSociété
20/06/202413h32Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ORMPOramed Pharmaceuticals Inc
20/06/202413h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORMPOramed Pharmaceuticals Inc
10/06/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORMPOramed Pharmaceuticals Inc
10/06/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
09/05/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORMPOramed Pharmaceuticals Inc
19/03/202414h00GlobeNewswire Inc.Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationNASDAQ:ORMPOramed Pharmaceuticals Inc
06/03/202423h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ORMPOramed Pharmaceuticals Inc
20/02/202414h30PR Newswire (US)Oramed Letter to ShareholdersNASDAQ:ORMPOramed Pharmaceuticals Inc
02/01/202419h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORMPOramed Pharmaceuticals Inc
22/09/202317h38PR Newswire (US)Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding CompanyNASDAQ:ORMPOramed Pharmaceuticals Inc
22/09/202300h11PR Newswire (US)Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyNASDAQ:ORMPOramed Pharmaceuticals Inc
21/09/202322h05GlobeNewswire Inc.Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.NASDAQ:ORMPOramed Pharmaceuticals Inc
13/09/202315h00GlobeNewswire Inc.Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderNASDAQ:ORMPOramed Pharmaceuticals Inc
02/08/202313h45PR Newswire (US)Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyNASDAQ:ORMPOramed Pharmaceuticals Inc
20/06/202313h55PR Newswire (US)Oramed to Present at the 83rd American Diabetes Association ConferenceNASDAQ:ORMPOramed Pharmaceuticals Inc
18/05/202313h55PR Newswire (US)Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitNASDAQ:ORMPOramed Pharmaceuticals Inc
15/05/202315h05PR Newswire (US)Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaNASDAQ:ORMPOramed Pharmaceuticals Inc
11/05/202323h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/05/202323h08Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/05/202322h53Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ORMPOramed Pharmaceuticals Inc
01/05/202322h45PR Newswire (US)Oramed Appoints Ben Shapiro to its Board of DirectorsNASDAQ:ORMPOramed Pharmaceuticals Inc
20/04/202312h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ORMPOramed Pharmaceuticals Inc
09/02/202313h55PR Newswire (US)Oramed Pharmaceuticals Issues Shareholder UpdateNASDAQ:ORMPOramed Pharmaceuticals Inc
12/01/202302h00PR Newswire (US)Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesNASDAQ:ORMPOramed Pharmaceuticals Inc
04/01/202313h55PR Newswire (US)Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of DiabetesNASDAQ:ORMPOramed Pharmaceuticals Inc
29/11/202214h40PR Newswire (US)Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and MetabolismNASDAQ:ORMPOramed Pharmaceuticals Inc
18/11/202211h43TipRanksOramed Pharma Up After Positive Clinical DataNASDAQ:ORMPOramed Pharmaceuticals Inc
17/11/202218h26PR Newswire (US)Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASHNASDAQ:ORMPOramed Pharmaceuticals Inc
14/11/202213h55PR Newswire (US)Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South KoreaNASDAQ:ORMPOramed Pharmaceuticals Inc
10/11/202222h30PR Newswire (US)Oramed Reports Third Quarter 2022 Financial ResultsNASDAQ:ORMPOramed Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ORMP

Dernières Valeurs Consultées

BITMOT
2786183
Gs Group Sc Jan34 Call Eur
COIN
AITRAGBP
BIT
NSCIT5443592
Galadriel Spe
LSE
52LZ
Sthn.pac.42b1ca
NYSE
YELP
Yelp
USOTC
SMPEF
Southern Empire Resources (QB)
COIN
IPUXUST
IPUX Token
TG
D1LN
Direct Line Insurance
SUSHI
NUETH
NuCypher
LSE
IPDM
Ishs Palladium$
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés